title: [Systemic therapy of muscle invasive bladder cancer - an update].
abstract: Urothelial cancer is a highly common tumor with increasing incidence worldwide and a peak in the seventh decade. Locally advanced disease has a significant risk for developing metastases. Neoadjuvant, platinum-containing combination chemotherapy improves survival over radical cystectomy. Chemotherapy with gemcitabine plus cisplatin shows equivalent efficacy with less toxicity to MVAC in metastatic setting. New therapy strategies, especially in elderly patients, are urgently needed.
authors.affiliation: Interne Abteilung mit Herzstation und Dialyse, Krankenhaus der Barmherzigen Brüder, Wien, Austria. dora.niedersuess-beke@bbwien.at
authors.forename: Dora
authors.initials: D
authors.lastname: Niedersüss-Beke
mesh_terms: D000367:Age Factors; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D003131:Combined Modality Therapy; D015653:Cystectomy; D005260:Female; D006801:Humans; D008297:Male; D020360:Neoadjuvant Therapy; D009361:Neoplasm Invasiveness / Q000473:pathology; D009367:Neoplasm Staging; D001743:Urinary Bladder / Q000473:pathology; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery